Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
904.80 | 91,049 Cr | 17.80 | 3.60 | 1.22 | 19.44 | 19.08 | 10.52 | |
2060.60 | 85,050 Cr | 45.78 | 5.56 | 0.00 | 11.45 | 12.34 | 6.26 | |
1155.45 | 66,705 Cr | 19.00 | 1.90 | 0.00 | 9.77 | 12.69 | 6.63 | |
5400.00 | 64,584 Cr | 27.47 | 4.84 | 0.83 | 17.69 | 18.13 | 11.95 | |
1996.00 | 56,343 Cr | 20.81 | 5.88 | 0.13 | 26.24 | 30.84 | 5.60 | |
1012.00 | 54,534 Cr | 64.79 | 11.35 | 0.12 | 14.23 | 15.05 | 8.94 | |
1472.50 | 37,765 Cr | 37.74 | 5.08 | 0.27 | 13.33 | 17.89 | 7.73 |
Aurobindo Pharma Limited, founded in 1986, specializes in developing, manufacturing, and marketing active pharmaceutical ingredients and generic formulations. With 29 manufacturing plants worldwide, it offers a broad product portfolio across major therapeutic areas.
Notably advancing in biotechnology, Aurobindo is focusing on biosimilars, supported by key regulatory milestones such as European and MHRA approvals. They're expanding manufacturing capacities to meet future biosimilar demands.
The company reported substantial financial performance for Q2FY26 with 6% YoY revenue growth driven by robust US and European markets, and 18% growth in European operations alone, solidifying their market presence.
Significant investments are made in manufacturing advancements, aligning with strategic expansion plans in biosimilars and injectable business, with future launches expected to boost topline growth.
Despite market challenges, Aurobindo maintains stable financial health, demonstrated by an impressive net cash position, continuous product filings, and a comprehensive global regulatory filing strategy.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
66,705 Cr
High Risk
19.0
26.2
1.5
1.9
1,278.00
994.35
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Aurobindo Pharma Ltd (AUROPHARMA) is currently trading at 1,155.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aurobindo Pharma Limited, founded in 1986, specializes in developing, manufacturing, and marketing active pharmaceutical ingredients and generic formulations. With 29 manufacturing plants worldwide, it offers a broad product portfolio across major therapeutic areas. Notably advancing in biotechnology, Aurobindo is focusing on biosimilars, supported by key regulatory milestones such as European and MHRA approvals. They're expanding manufacturing capacities to meet future biosimilar demands. The company reported substantial financial performance for Q2FY26 with 6% YoY revenue growth driven by robust US and European markets, and 18% growth in European operations alone, solidifying their market presence. Significant investments are made in manufacturing advancements, aligning with strategic expansion plans in biosimilars and injectable business, with future launches expected to boost topline growth. Despite market challenges, Aurobindo maintains stable financial health, demonstrated by an impressive net cash position, continuous product filings, and a comprehensive global regulatory filing strategy.
Over the past 52 weeks, Aurobindo Pharma Ltd has traded between a low of ₹994.35 and a high of ₹1,278.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aurobindo Pharma Ltd has a market capitalization of approximately 66,705.07. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aurobindo Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 19.00 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 66,705.07 Cr, Aurobindo Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aurobindo Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aurobindo Pharma Ltd is 19.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Aurobindo Pharma reported an 8.4% year-on-year revenue growth to ₹8,646 crore and a 7.5% increase in net profit to ₹909.8 crore. EBITDA margin expanded to 20.5%.
The most significant announcement is the 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay over five years to promote domestic manufacturing of biologics and biosimilars, directly benefiting companies like Aurobindo.
The Directorate General of Foreign Trade (DGFT) has imposed a Minimum Import Price (MIP) of ₹2,216 per kilogram, or about $24, on Pen-G. Similar price floors have been set for its derivatives, 6-APA and Amoxicillin.
Auro Pharma Ltd, a wholly-owned subsidiary of Aurobindo Pharma Ltd, acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories.
Bearish
2
Neutral
7
Bullish
5
Bearish
27
Neutral
7
Bullish
12
Bearish
25
Neutral
0
Bullish
7
FDA Approval
Acrotech Biopharma (Aurobindo Pharma step‑down subsidiary) announced US FDA approval of ADQUEY™ (difamilast 1%) ointment, a non‑steroidal topical PDE4 inhibitor, for mild‑to‑moderate atopic dermatitis in patients aged ≥2 years.
Newspaper Publication
Aurobindo Pharma submitted copies of newspaper ads for its Q3 and nine-month financial results for the year ending December 31, 2025, published on February 11, 2026.
Regulatory Filing
Aurobindo Pharma announces the completion of a US FDA inspection at its Unit-VII in Jedcherla, where 9 procedural observations were noted.
Restructuring
Aurobindo Pharma has announced the merger of its wholly owned subsidiaries, Curateq Biologics and Auro Vaccines, approved by the Board.
Acquisition Announcement
Aurobindo Pharma announces acquisition of a 26% stake in Garuda Renewables Private Limited, investing Rs. 66 crores to enhance renewable energy procurement.
Change in Directors
Dr. Punita Kumar-Sinha appointed as Non-Executive Independent Director, while Dr. Deepali Pant Joshi completes her term and retires from the board.
